U.S. markets closed

Exagen Inc. (XGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.6250-0.0750 (-2.78%)
At close: 04:00PM EST
2.6250 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.7000
Bid1.0600 x 1800
Ask2.6400 x 1100
Day's Range2.6100 - 2.8150
52 Week Range2.1000 - 11.6900
Avg. Volume82,801
Market Cap42.839M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.8200
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exagen Inc.
    Daily – Vickers Top Buyers & Sellers for 07/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • Zacks

    Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

    Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Exagen Inc. Reports Third Quarter 2022 Results

    Medicare Reimbursement ReturnsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE® CTD test, including AVISE® Lupus, recognized revenue of $12.8 million in the third quarter of 2022.Delivered 35,569 AVISE CTD tests, including AVISE Lupu

  • GlobeNewswire

    Exagen Inc. to Participate in Fourth Quarter Investor Conferences

    SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Thursday, November 17, 2022, at the Westin NY Grand Central Hotel Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Panel Presentation - Diagnostics Tool Time: No